Activation of the human FP prostanoid receptor disrupts mitosis progression and generates aneuploidy and polyploidy by unknown
Abstract. Studies have shown prostaglandin F2a (PGF2a)
to be an endogenous tumor promoter in mouse models of
skin carcinogenesis; however, the mechanisms by which
PGF2a affects cell cycle events remain unknown. Here we
performed cell cycle analyses on HEK cells stably ex-
pressing the human FP receptor and found that treatment
with PGF2a delays mitosis and is associated with an in-
creased expression of cyclin B1 and Cdc2 kinase activity.
In addition, multipolar spindles and misaligned chromo-
somes were observed in a significant proportion of cells
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treated with PGF2a. Defective cytokinesis was also ob-
served which resulted in gross aneuploidy and poly-
ploidy. Expression of dominant negative Rho attenuated
the cell cycle delay and prevented the generation of mi-
cronuclei following treatment with PGF2a. This suggests
that FP receptor activation of Rho signaling by PGF2a can
interfere with nuclear division. Aneuploidy is associated
with genomic instability and may underlie the tumor-pro-
moting properties of PGF2a. 
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Prostaglandin F2a (PGF2a) belongs to the family of pros-
tanoids that are derived from arachidonic acid by the se-
quential actions of the cyclooxygenases (COXs) and the
respective prostaglandin (PG) and thromboxane (Tx)
synthases. Prostanoids, which include PGE2, PGF2a,
PGI2, PGD2, and TxA2, are synthesized in nearly all hu-
man tissues and act in an autocrine/paracrine manner to
elicit a broad spectrum of physiological and pathophysi-
ological actions. Some of these actions include inflam-
mation, wound healing, kidney function, bone metabo-
lism, immune response, and reproductive function [1]. In
the context of pathological conditions, specifically in tu-
mors, a large body of evidence from epidemiological, in
vivo, and in vitro studies suggests the involvement of
COX-2 and its downstream effectors PGE2 and PGF2a in
multistage carcinogenesis, particularly in tumor promo-
tion [2, 3]. More recent studies using transgenic mice
have suggested a direct prooncogenic role for COX-2
and have shown that targeted overexpression of COX-2
is sufficient to induce hyperplasia, dysplasia, and tumo-
rigenesis [4, 5]. Furthermore, PGE2 has been found to
participate in tumorigenesis by inhibiting apoptosis, pro-
moting cell proliferation and survival, and by inducing
angiogenesis and immunosuppression [6–8]. Positive
feedback between COX-2 and PGE2 has also been sug-
gested to facilitate malignant transformation [9]. Com-
pared to PGE2, there is less information available on the
molecular mechanisms involved in the tumor-promoting
activity of PGF2a.
PGF2a binds to what has been defined as the FP prostanoid
receptor, which belongs to the family of heterotrimeric G
protein-coupled receptors (GPCRs) [10]. The FP pros-
tanoid receptor is coupled to Gq, and stimulation of the
receptor by PGF2a leads to the activation of phospholipase
C-b (PLCb) signaling followed by downstream activation
of protein kinase C (PKC) and an elevation in intracellu-
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lar Ca2+ [10, 11]. The PGF2a-induced activation of PKC
has been demonstrated to activate the Raf/MEK/MAP ki-
nase signaling cascade and to stimulate cell proliferation
[12, 13]. In addition, activation of MAP kinase by PGF2a
can be inhibited by pertussis toxin, suggesting that FP re-
ceptor can also couple to Gi [14]. Recent studies using
HEK 293 cells stably expressing alternative mRNA splice
variants of the ovine FP receptor demonstrated that PGF2a
could stimulate the activation of Rho GTPase signaling
leading to actin-mediated changes in cell morphology and
activation of focal adhesion kinase [15].
The growth of cells in a tissue essentially represents a bal-
ance between cellular death or apoptosis, and cellular pro-
liferation. Growth will occur if apoptosis decreases and
proliferation increases, or a combination thereof. Cellular
proliferation reflects the activity of the cell cycle, which is
driven by the interaction of cyclins with the cyclin-depen-
dent kinases (CDKs) [16]. Different cyclin-CDK com-
plexes are activated at different points in the cell cycle.
The transition of cells from G2 to mitosis is dependent
upon the completion of several events that culminate in
the activation of the cyclin B/Cdc2 kinase complex [17]. 
During mitosis, cells undergo nuclear division in which
the duplicated chromosomes are partitioned equally be-
tween the two daughter cells. The mitotic spindle plays an
essential role in this complex movement, which depends
on the proper assembly, orientation and attachment of the
spindle to the chromosomes. Missegregation of the du-
plicated chromosomes can result from abnormal spindles
and/or misalignment of the chromosomes and can give
rise to the gain or loss of chromosomes (aneuploidy). Ge-
nomic instability is a hallmark of tumorigenesis and the
development of polyploidy and aneuploidy is one estab-
lished mechanism for generating genomic instability dur-
ing tumorigenesis. 
Using the mouse skin model of multistage carcinogene-
sis, PGF2a has been identified as an endogenous tumor
promoter [18, 19]. The exact mechanisms by which
PGF2a promotes skin tumorigenesis are unknown but
could involve increased cell proliferation, decreased
apoptosis or immune surveillance, or combinations of
these processes. Studies have shown that PGF2a can stim-
ulate cellular proliferation, although not specifically in
the context of skin tumorigenesis [20, 21]. In the present
study we performed a detailed cell cycle analysis on HEK
cells stably expressing the human FP receptor. Activation
of the FP receptor by PGF2a was found to disrupt mitosis
progression, generating abnormal mitotic spindles and
misaligned chromosomes. In addition, prolonged stimu-
lation with PGF2a lead to the development of polyploidy
and aneuploidy. Expression of dominant negative Rho at-
tenuated the changes in cell cycle progression and res-
cued the aneuploidy caused by PGF2a treatment. These
findings show that PGF2a-induced Rho signaling inter-
feres with nuclear division and suggest that the tumor-
promoting activity of PGF2a could be a consequence of
resulting genomic instability. 
Materials and methods
Reagents. Dulbecco’s modified Eagle’s medium (DMEM),
Opti-MEM, fetal bovine serum (FBS), G418, gentamicin,
and hygromycin B were purchased from Life Technolo-
gies. [g-32P]ATP was purchased from Amersham Bio-
sciences. PGF2a was purchased from Cayman Chemicals.
Bromodeoxyuridine (BrdU) and propidium iodide, and
anti-a-tubulin monoclonal antibody were purchased from
Sigma and prepared in phosphate-buffered saline (PBS) as
1 mM and 1 mg/ml stock solutions, respectively. Anti-a-
tubulin monoclonal antibody was purchased from Sigma.
Monoclonal anti-cyclin B1 and anti-BrdU antibodies were
purchased from BD Transduction Laboratories. Cdc2 rab-
bit polyclonal (C-19) and mouse monoclonal (B-6) anti-
bodies were purchased from Santa Cruz Biotechnology.
Histone H1 and monoclonal anti-actin antibodies were
purchased from Calbiochem. Texas red isothiocyanate-
conjugated phalloidin, Alexa Fluor 488-, and Alexa Fluor
594-conjugated anti-mouse secondary antibodies were
purchased from Molecular Probes. Horseradish peroxi-
dase (HRP)-conjugated anti-mouse secondary antibody
was purchased from Promega. The FuGENE 6 transfec-
tion kit was purchased from Roche. Protein G-Sepharose
was purchased from Amersham Biosciences. 
Cell culture and transient transfections. HEK 293
EBNA cells (Invitrogen) stably expressing the human FP
receptor (hFP-HEK) and empty vector (pCEP4)-trans-
fected cells (pCEP4-HEK) were maintained in DMEM
supplemented with 10% FBS, 250 mg/ml G418, 100 mg/
ml gentamicin, and 200 mg/ml hygromicin B. Hygro-
micin B is the selection drug for pCEP4-containing cells.
Transient transfections using the FuGENE 6 kit were per-
formed according to the manufacturer’s manual. Briefly,
cells were split into 35-mm dishes or six-well plates and
incubated at 37 °C overnight. Before transfection, 6 ml of
FuGENE 6 reagent was incubated with 100 ml of Opti-
MEM for 5 min at room temperature and then 2 mg of
plasmid DNA was added consisting of one plasmid en-
coding enhanced green fluorescent protein (EGFP) and a
second encoding N19RhoA (used at a ratio of 1:3). After
30 min at room temperature, the FuGENE/DNA solution
was added dropwise to the cells and swirled gently, after
which the cells were incubated at 37 °C for 24 h and were
then used for either cell cycle analysis or immunofluores-
cence staining.
Synchronization. A thymidine-mimosine double-block
protocol was used to synchronize cells in late G1 phase.
Cells were plated at a density of ~5¥105 in 10-cm dishes
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and incubated at 37 °C overnight. Cells were then treated
with thymidine (2.5 mM; Sigma) for 16 h, after which
thymidine was washed away. Eight hours later, mimosine
(400 mM; Calbiochem) was added to the cultures for an-
other 16 h. This protocol results in synchronization of
more than 90% of cells in the late G1 phase.
BrdU incorporation and cell cycle analysis. Cell cycle
analysis was investigated using anti-BrdU/propidium io-
dide double staining. For each experiment, cells were
plated at a density of ~5¥105 in 10 cm-dishes and incu-
bated at 37 °C for 24 h to permit adherence. Cells were
then treated with either vehicle (2% sodium bicarbonate)
or 1 mM PGF2a and 24 and 48 h later the cells were pulsed
by the addition of 10 mM BrdU to the medium for 10 min
at 37 °C. The cells were trypsinized, washed with 1%
bovine serum albumin (BSA) in PBS and resuspended in
200 ml ice-cold PBS. Fixation was performed by adding
cells dropwise into 5 ml of cold 70% ethanol (glass test
tubes) while vortexing and were incubated on ice for an
additional 30 min. Cells were then treated at room tem-
perature for 30 min with 2 M HCl containing 0.5% Triton
X-100 to denature DNA and neutralized by washing once
with 0.1 M borax, pH 8.5. Indirect immunofluorescence
was performed by incubating the cells at room tempera-
ture for 1 h (or 4 °C overnight) with anti-BrdU mono-
clonal antibody (1:100) diluted in PBS containing 0.5%
Tween and 1% BSA, followed by incubation at room
temperature for 1 h with FITC-labeled anti-mouse IgG
(1:500) at room temperature for 1 h. The cells were
washed once with PBS and resuspended in 0.5 ml of PBS
containing 5 mg/ml of propidium iodide and analyzed us-
ing a FACScan flow cytometer (Arizona Cancer Center
core facilities). The percentage of cells in G1/G0, S, and
G2/M were determined using the CellQuest program
(BD Biosciences). For cell cycle analysis of EGFP- and
N19Rho-transfected cells, cells were prefixed in 1%
formaldehyde in PBS on ice for 1 h and then fixed in 70%
ethanol at 4 °C overnight. After one wash with PBS, cells
were incubated for 30 min in 50 mg/ml propidium iodide
solution containing 100 mg/ml RNase A. CellQuest and
Modfit programs were used to select cells containing
EGFP and to determine cell cycle distribution, respec-
tively. 
Immunoblotting. Cells were plated at a density of ~1¥106
in 10 cm dishes and 24 h later 1 mM PGF2a was added and
the cells were incubated for another 24 h at 37 °C. Cell
lysates were prepared and immunoblotting was per-
formed as follows. Cells were washed twice with cold
PBS and lysed on ice in 500 ml RIPA buffer consisting of
150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA,
1% NP-40, 0.5% sodium deoxycholate, 10 mM sodium
fluoride, 10 mM disodium pyrophosphate, 0.1% SDS,
1 mM PMSF, 1 mM sodium orthovanadate, 10 mg/ml leu-
peptin, and 10 mg/ml aprotinin. The samples were rotated
at 4 °C for 30 min and centrifuged at 14,000 g for 10 min.
The supernatants were measured for protein concentra-
tions (Bradford assay) and 40 mg of protein was loaded on
10% SDS-PAGE gels, electrophoresed, and transferred to
nitrocellulose membranes. The membranes were incu-
bated at room temperature for 1 h with blocking buffer
consisting of 5% BSA and 0.1% Tween 20 in TBS, fol-
lowed by an overnight incubation with monoclonal anti-
cyclin B1 or monoclonal anti-Cdc2 antibodies (diluted
1:1000 with blocking buffer). HRP-conjugated anti-
mouse secondary antibody was used at a dilution of
1:10,000. Immunoreactivity was detected by SuperSignal
enhanced chemiluminescence (Pierce). To ensure equal
loading of protein, the membranes were reprobed as
above after stripping the membranes for 30 min at 55 °C
in a stripping buffer consisting of 2% SDS, 62.5 mM Tris
(pH 7.6), and 100 mM b-mercaptoethanol. 
In vitro Cdc2 kinase assay. The Cdc2 kinase assay was
performed according to published procedures as follows
[22]. Cells were washed once in ice-cold PBS and incu-
bated for 30 min on ice in a lysis buffer consisting of
50 mM Tris-HCl (pH 7.4), 0.5% NP-40, 150 mM NaCl,
50 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF,
10 mg/ml leupeptin, and 10 mg/ml aprotinin. The samples
were centrifuged at 12,000 rpm for 10 min and 500 mg of
protein from the supernatant was immunoprecipitated for
3 h at 4 °C with 2 mg of polyclonal C-19 anti-Cdc2 anti-
body, and 20 ml of protein G-Sepharose beads (50% w/v).
The beads were washed four times in lysis buffer and
twice in buffer consisting of 50 mM HEPES (pH 7.4), 10
mM MgCl2, and 1 mM dithiothreitol. The samples were
equally divided and one set was used for immunoblotting
with anti-Cdc2 monoclonal antibody and the second set
was used for the kinase assay. The assay was carried out
for 30 min at room temperature in 20 ml of kinase buffer
consisting of 50 mM HEPES (pH 7.4), 10 mM MgCl2,
5 mM ATP, 1 mM dithiothreitol, 5 mg histone H1, and
10 mCi [g-32P]ATP (3000 Ci/mmol). The assay was termi-
nated by adding 5 ml of 5¥ sample loading buffer and
boiled for 5 min at 95 °C. The samples were fractionated
by SDS-PAGE, dried, and subjected to autoradiography
to visualize the incorporation of 32P into histone H1. 
Immunofluorescence microscopy. Immunofluorescence
microscopy was performed using an Olympus IX70 mi-
croscope and ¥60 oil immersion and ¥20 objectives.
Images were acquired using an Olympus Digital camera
and MagnaFire 2.1 acquisition software, and were pro-
cessed using Adobe Photoshop software. For antibody
staining, transfected and non-transfected cells were seed-
ed on poly-lysine-treated coverslips in six-well plates.
After treatment with PGF2a for the indicated times, cells
were washed once in PBS and fixed for 15 min in 4%
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paraformaldehyde in PBS (freshly prepared). The cells
were then rinsed three times in 0.1 M glycine (pH 7.4)
and permeabilized for 10 min in 2¥SSC (30 mM NaCl,
300 mM sodium citrate) containing 0.1% Triton X-100.
The cells were washed 3 additional times in PBS and then
incubated for 30 min in blocking buffer consisting of
2¥SSC, 0.05% Triton X-100, 2% goat serum, 1% BSA
followed by a 1-h incubation at room temperature in
blocking buffer containing a 1:1000 dilution of Texas red
isothiocyanate-conjugated with phalloidin. After a brief
wash in PBS, cells were stained with 4, 6-diamidino-2-
phenylindole (DAPI) (1 mg/ml) for 10 min and washed
three times in PBS and once in water. Coverslips were
mounted using p-phenylenediamine. For a-tubulin stain-
ing, cells were prefixed in a solution containing 4%
formaldehyde, 100 mM HEPES (pH 6.8), 5 mM EGTA,
10 mM MgCl2, and 0.2% Triton X-100 for 10 min at room
temperature and then fixed in cold methanol for 10 min at
–20 °C. After several washes in PBS, the cells were
blocked with 2% BSA in TBST for 30 min at room tem-
perature and then incubated for 1 h with monoclonal anti-
a-tubulin antibodies (1:1000 in blocking buffer), fol-
lowed by a 1-h incubation with Alexa Fluor 488-conju-
gated secondary antibodies (1:1000 dilution in blocking
buffer). 
Results 
PGF2a treatment of HEK cells expressing the human
FP receptor leads to cell cycle delay in G2/M. Flow cy-
tometry was used to investigate the effect of PGF2a on cell
cycle progression of HEK cells expressing the human FP
prostanoid receptor. Empty vector pCEP4-transfected cells
were used as the control. Asynchronous cultures were
treated with either 1 mM PGF2a or vehicle for 24 or 48 h
and were pulse labeled with 10 mM BrdU for 15 min to
mark the S phase of cells undergoing DNA replication. Ad-
ditionally, the cells were stained with propidium iodide to
determine the nuclear DNA content. As shown in figure 1,
both vehicle-treated and PGF2a-treated pCEP4-HEK cells
and vehicle-treated hFP-HEK cells showed similar cell cy-
cle distribution profiles. In contrast, in PGF2a-treated hFP-
HEK cells, the G1 population was reduced to 30% in the
treated cells (compared to 42% in the untreated cells),
while there was a corresponding increase in the G2/M pop-
ulation from 12% to 24.5%. These changes were evident
after both 24 and 48 h of treatment with PGF2a. The S
phase population remained relatively constant. The con-
stant S phase population and the similar profile of S phase
distribution before and after treatment indicates that PGF2a
had no detectable effects on DNA replication as measured
by BrdU incorporation. The increase in G2/M population,
on the other hand, suggests either a delay in the G2/M tran-
sition or in the exit from mitosis.
To better understand the effect of PGF2a on the cell cycle,
cells were synchronized in late G1 by a double thymi-
dine-mimosine block and then PGF2a or vehicle was
added at the time of release from the block. As shown in
figure 2, at the time of release (0 h), more than 90% of ve-
hicle-treated pCEP4-HEK cells were in G1; after 6 h,
they progressed into S phase and by 9 h a small fraction
of cells had exited mitosis. After 15 and 18 h only a neg-
ligible G2/M peak remained, as the majority of the vehi-
cle-treated pCEP4-HEK cells had exited mitosis and ac-
cumulated in G0/G1. PGF2a-treated pCEP4-HEK cells
and vehicle-treated hFP-HEK cells showed profiles of
cell cycle progression that were very similar to the vehi-
cle-treated pCEP4-HEK cells. In contrast, PGF2a treat-
ment of hFP-HEK cells caused a significant delay in G2/
M, such that by 9 h, none of these cells had exited mito-
sis. Even after 15 and 18 h, the G2/M population of
PGF2a-treated hFP-HEK cells was minimally depleted
compared with vehicle-treated hFP-HEK cells. Taken to-
gether, these data indicate that PGF2a treatment does not
cause a complete cell cycle arrest, rather, it delays G2/M
phase progression in hFP-HEK cells. 
PGF2a delays mitosis in hFP-HEK cells.The progression
through G2 and M phases is orchestrated by the sequential
activation and inactivation of the Cdc2/cyclin B1 complex.
To ensure the inheritance of complete and accurate copies
of the genome there is a G2/M checkpoint that monitors
the presence of DNA damage. If damage is detected, the
G2/M checkpoint will inhibit the activation of the Cdc2/
cyclin B1 complex, thereby preventing entry into mitosis
until the damage has been repaired [23]. To further delin-
eate the observed delay in the G2/M phase in hFP-HEK
cells treated with PGF2a, cyclin B1 expression and Cdc2
kinase activity were assessed by immunoblot analysis and
in vitro kinase assay, respectively. Surprisingly, as shown
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Figure 1. PGF2a increases the G2/M population in HEK cells stably
expressing the human FP prostanoid receptor. Histograms of cell
cycle distributions of HEK cells stably transfected with either the
human FP prostanoid receptor (hFP-HEK) or with the empty vector
(pCEP4-HEK) and treated with either vehicle (2% Na2CO3) or
1 mM PGF2a for 24 or 48 h. BrdU incorporation, propidium iodine
labeling, and two-dimensional flow cytometry were carried out as
described in Materials and methods. Data are expressed as a per-
centage of the number of cells in each phase of the cell cycle and
represent the means ± SEs from four independent experiments. 
in figure 3A, cyclin B1 protein expression was found to in-
crease following treatment of hFP-HEK cells with PGF2a.
These data indicate that the delay in G2/M was not due to
a decrease in cyclin B1 protein expression. As shown in
figure 3B, there was a corresponding increase in Cdc2 ki-
nase activity following the treatment of hFP-HEK cells
with PGF2a, which was not observed in PGF2a-treated con-
trol pCEP4-HEK cells. These findings indicate that the ac-
tions of PGF2a to cause a G2/M delay in hFP-HEK cells
are likely to occur following entry into mitosis.
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Figure 2. PGF2a causes G2/M delay in HEK cells expressing the human FP prostanoid receptor. DNA profiles of hFP-HEK and pCEP4-HEK
cells synchronized in late G1 with the double thymidine-mimosine block. Samples were fixed and stained with propidium iodine at the time
of release (0 h), 6 h after release, and then every 3 h up to 18 h after release. For all graphs, the y-axis is cell number and the x-axis is DNA
content. Representative of four independent experiments.
Figure 3. PGF2a treatment of HEK cells stably expressing the human
FP prostanoid receptor increases expression of cyclin B1 (A) and in-
creases Cdc2-mediated phosphorylation of histone H1 (B). (A) Upper
panel: immunoblot of lysates prepared from hFP-HEK and pCEP4-
HEK cells that had been treated with either vehicle (V) or 1 mM
PGF2a for 24 h. Blots were probed with anti-cyclin B1 and anti-actin
antibodies as described in Materials and methods. Lower panel:
quantitative analysis of three independent experiments by densitom-
etry of cyclin B1 immunoreactivity normalized to actin immunore-
activity (means ± SEs). (B) Upper panel: autoradiograph of Cdc2 ki-
nase activity (phosphorylation of histone H1) and immunoblot of
Cdc2 kinase expression in lysates prepared from hFP-HEK and
pCEP4-HEK cells that had been treated with either vehicle (V) or
1 mM PGF2a for 24 h. Cdc2 kinase assays and Cdc2 immunoblotting
were done as described in Materials and methods. Lower panel: quan-
titative analysis of three independent experiments by densitometry of
Cdc2 kinase activity (histone H1 phosphorylation) normalized to
Cdc2 immunoreactivity (means ± SEs). 
PGF2a treatment leads to the generation of multipolar
mitotic spindles and misaligned chromosomes in hFP-
HEK cells. Like the G2/M checkpoint, there is a mitotic
spindle assembly checkpoint which functions to prevent
cells with misaligned chromosomes from exiting mitosis
prematurely. Failure of this checkpoint can result in ane-
uploidy in the daughter cells and contributes to genomic
instability. So far, all known delays in mitosis are medi-
ated by the mitotic spindle assembly checkpoint [24]. Be-
cause PGF2a delayed mitosis in hFP-HEK cells, we were
interested in further assessing the integrity of mitotic
spindles and examining the chromosome alignment in
hFP-HEK cells following treatment with PGF2a. The re-
sults of these studies are shown in figures 4 and 5. In con-
trast to pCEP4-HEK control cells and vehicle-treated
hFP-HEK cells, which showed essentially normal bipolar
spindle and chromosome alignment, PGF2a-treated hFP-
HEK cells exhibited a significant portion of cells with
multipolar spindles (fig. 4, panels a–c) and misaligned
chromosomes (fig. 4, panels d–f). These multipolar spin-
dles were often accompanied by poles of different sizes
and with disorganized arrays of microtubules and mis-
aligned chromosomes. The bottom panel of figure 4
shows that the percentage of hFP-HEK cells with multi-
polar spindles increased ~6-fold 48 h after addition of
PGF2a, and then decreased at 96 h, but was still ~2.5-fold
higher than in the untreated cells. The percentage of hFP-
HEK cells with misaligned chromosomes, however, in-
creased markedly both 48 h and 96 h after the addition of
PGF2a (~3.5- and 8-fold, respectively). The outcome of
these multipolar spindles and misaligned chromosomes is
that free and/or lagging chromosomes will distribute ran-
domly to the daughter cells giving rise to either a gain or
loss of chromosomes (aneuploidy). Figure 5, in fact,
shows that in hFP-HEK cells treated with PGF2a there
was a dramatic increase in the percentage of hFP-HEK
cells containing micronuclei around the major interphase
nuclei, which is a reflection of aneuploidy. Thus, the per-
centage of hFP-HEK cells containing micronuclei in-
creased from ~2% at the zero time point to ~44% after
96 h of treatment with PGF2a. There was also an increase
in hFP-HEK cells containing two or more nuclei (poly-
ploidy) following PGF2a treatment; from ~1% at the zero
time point to ~10% after 96 h of treatment. 
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Figure 4. PGF2a induces multipolar mitotic spindles and misaligned chromosomes in HEK cells stably expressing the human FP
prostanoid receptor. Upper panels: photomicrographs of hFP-HEK cells after 48 h treatment with 1 mM PGF2a followed by fluorescence
labeling of mitotic spindles with anti-a-tubulin antibody (green) and of nuclear DNA with DAPI (blue). a–c, examples of multipolar
spindles; d, e, examples of misaligned chromosomes; f, midbody from three polar divisions. Scale bar, 10 mm. Lower panels: the rela-
tive percentages of multipolar spindles and misaligned chromosomes in mitotic cells stably transfected with empty vector (pCEP4-
HEK) or the human FP prostanoid receptor (hFP-HEK) after treatment with 1 mM PGF2a for 0, 48 or 96 h. Data are the means ± SEs
from three independent experiments.
PGF2a treatment induces abnormal cortical activity
during cytokinesis. The presence of polyploidy in PGF2a-
treated hFP-HEK cells suggests abnormalities during cy-
tokinesis (cell division) as well as during mitosis. This
would not be unexpected given that mitosis and cytokine-
sis are related events requiring close temporal and spatial
coordination. Phalloidin staining of actin and fluores-
cence microscopy were, therefore, used to determine if
the presence of multipolar spindles and misaligned chro-
mosomes was associated with any abnormalities in cy-
tokinesis in hFP-HEK cells treated with PGF2a. We found
that while control pCEP4-HEK and vehicle-treated hFP-
HEK cells showed essentially normal patterns of actin
staining, PGF2a-treated hFP-HEK cells showed numerous
instances of abnormal staining. Figure 6 shows several
examples of this abnormal staining. Thus, the PGF2a
treated hFP-HEK cells shown in panels figure 6A and B
showed the presence of abnormal cortical blebs in cells
undergoing cytokinesis. Figure 6C shows the presence of
a PGF2a-treated hFP-HEK cell containing multiple inter-
phase nuclei within a spherical cortex of actin staining,
which can result from a failure of cytokinesis. Figure 6D
shows the consequence of this abnormal cytokinesis,
which is a multi-nucleated cell undergoing mitosis. Nu-
merous examples of multinucleated hFP-HEK cells fol-
lowing PGF2a treatment are shown in figure 5 at lower
magnification. 
Expression of N19Rho attenuates the cell cycle changes
and rescues aneuploidy following treatment of hFP-
HEK cells with PGF2a. We have previously reported that
PGF2a can activate Rho-mediated signaling in HEK cells
stably expressing the ovine FPA and FPB receptors and
that this Rho signaling leads to the activation of focal ad-
hesion kinase and the formation of actin stress fibers
[15]. The upper panel of figure 7 shows that PGF2a can
also induce the formation of actin stress fibers in HEK
cells stably expressing the human FP receptor, but not in
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Figure 5. PGF2a induces genomic instability in HEK cells stably ex-
pressing the human FP prostanoid receptor. Upper panel: photomi-
crographs of HEK cells stably transfected with empty vector
(pCEP4-HEK) or the human FP prostanoid receptor (hFP-HEK) fol-
lowing 96 h treatment with either vehicle (2% Na2CO3) or 1 mM
PGF2a and fluorescence labeling of nuclear DNA with DAPI. Scale
bar, 10 mm. Lower panel; histograms of the numbers of cells with
micronulei or multiple nuclei following 0, 48 or 96 h treatment with
1 mM PGF2a. Data are the means ± SEs from five independent ex-
periments. Nuclei with free chromosomes, lagging chromosomes,
abnormal shapes and fragmented nuclei were counted as micronu-
clei (aneuploidy). Cells with two or more nuclei were counted as
multinuclei (polyploidy).
Figure 6. PGF2a induces abnormal cortical activity and generation
of multiple nuclei in HEK cells stably expressing the human
prostanoid receptor. Photomicrographs of hFP-HEK cells after 96 h
treatment with 1 mM PGF2a followed by fluorescence labeling of
cortical actin with Texas Red-conjugated phalloidin (red) and of nu-
clear DNA with DAPI (blue). Scale bar, 10 mm. (A, B) Examples of
abnormal blebs. (C) Example of abnormal mitotic actin staining in
a cell with two interphase nuclei. (D) Example of multinucleated
cell undergoing mitosis. 
the control cells stably transfected with the pCEP4 vector
alone. The Rho inhibitor, C3 exoenzyme and the ROCK
inhibitor, Y27632, blocked the PGF2a-mediated forma-
tion of actin stress fibers in hFP-HEK cells (data not
shown). We hypothesized that PGF2a-induced Rho sig-
naling might underlie the mechanism of defective corti-
cal activity and failure of cytokinesis. 
For these experiments N19RhoA, the dominant negative
form of RhoA, was co-transfected with EGFP into hFP-
HEK cells. EGFP was used to select the positive cells
and cell cycle analysis and quantitation of cells contain-
ing micronuclei/multinuclei were carried out 24 and 48
h after PGF2a treatment, respectively. A 96-h time point
could not be examined because with the time required
for the transfection itself, the cells were postconfluent
and were growing in layers by 96-h. As shown in the
middle panel of figure 7, treatment of hFP-HEK cells
with PGF2a resulted in a twofold increase in the number
of cells in G2/M which increased from 12% to 22%.
Concomitantly, the number of cells in G0/G1 decreased
by roughly the same amount from 43% to 32%, while the
S phase population remained unchanged. Transfection
with dominant negative N19RhoA alone caused a slight
increase in the number of cells in G0/G1, from 43% to
48%, while causing slight decreases of a similar magni-
tude in the number of cells in S and G2/M. The effects of
N19RhoA in the absence of PGF2a treatment suggest a
slowing of the cell cycle, which is consistent with the
well-known function of Rho in the progression from G1
to S. Rho signaling, however, also appears to be impor-
tant with respect to the changes in cell cycle distribution
that are mediated by PGF2a in hFP-HEK cells. Thus, the
middle panel of figure 7 shows that in hFP-HEK cells
transfected with N19RhoA, the effect of PGF2a to in-
crease the number of cells in G2/M was essentially
blocked. The effect of PGF2a to decrease the number of
cells in G0/G1, however, was only slightly reduced in
hFP-HEK cells transfected with N19RhoA. These ef-
fects were accompanied by a moderate increase in the
number of cells in S phase. In contrast, the lower panel
of figure 7 shows that the effect of PGF2a to increase the
number of hFP-HEK cells with micronuclei following
treatment with PGF2a was almost completely abrogated
in N19RhoA-transfected hFP-HEK cells, going from
about threefold to almost nothing. The effect of PGF2a to
increase the number of hFP-HEK cells with multiple nu-
clei could not be observed in N19RhoA-transfected hFP-
HEK cells because the blockade of Rho signaling itself
caused a large increase in the number of cells with mul-
tiple nuclei even in the absence of PGF2a treatment.
Taken together these findings suggest that the observed
cell cycle delay and aneuploidy generated by PGF2a
treatment of hFP-HEK cells is mediated at least in part
by a Rho signaling pathway. 
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Figure 7. Dominant negative N19RhoA attenuates the cell cycle
delay and rescues aneuploidy caused by PGF2a treatment of HEK
cells stably expressing the human FP prostanoid receptor. Upper
panel: photomicrographs of HEK cells stably transfected with
empty vector (pCEP4-HEK) or the human FP prostanoid receptor
(hFP-HEK) following 1 h treatment with either vehicle (2%
Na2CO3) or 1 mM PGF2a and fluorescence labeling of actin stress
fibers with Texas Red-conjugated phalloidin. Scale bar, 10 mm.
Middle panel: cell cycle distribution of hFP-HEK cells transiently
transfected with EGFP alone or EGFP plus N19RhoA, followed by
treatment with either vehicle or 1 mM PGF2a for 24 h. Data are the
means ± standard errors from four independent experiments.
Lower panel: number of cells with micronuclei or multiple nuclei
that were transiently transfected with either control plasmid or
plasmid encoding N19RhoA and 24 h later were treated with 1 mM
PGF2a for 48 h. Data are the means ± SEs from five independent
experiments. Cells were stained with DAPI to label nuclear DNA
and then examined and quantified by fluorescence microscopy.
Micronuclei and multiple nuclei were defined as in the legend to
figure 5.
Discussion 
The present study was aimed at exploring the possible
role of PGF2a signaling in the cell cycle by utilizing a
HEK cell line stably expressing the human FP
prostanoid receptor. Here we report that PGF2a treat-
ment of hFP-HEK cells leads to a delay in mitosis pro-
gression with elevated levels of cyclin B1 and increased
Cdc2 kinase activity. In addition, PGF2a treatment of
hFP-HEK cells was found to generate abnormal mitotic
spindles and misaligned chromosomes resulting in the
accumulation of multiple nuclei and aneuploidy. These
findings are reminiscent of the outcomes of dysregula-
tion of the centrosomal proteins involved in kineto-
chore-microtubule attachment [25, 26]. Given that all
known delays in mitosis are due to the activation of the
mitotic spindle assembly checkpoint, we postulate that
the generation of abnormal mitotic spindles and mis-
aligned chromosomes caused by the treatment of hFP-
HEK cells with PGF2a activates the mitotic spindle
checkpoint and delays the onset of anaphase. Thus, if
hFP-HEK cells fail to correct the abnormalities in chro-
mosome alignment during a prolonged mitosis, they are
likely to exit mitosis with the generation of one or more
cells with altered genomes. 
The observation of multinucleated cells after the treat-
ment of hFP-HEK cells with PGF2a further supports the
notion that imbalanced Rho GTPase activity results in
defective actomyosin contractility and failure of cytoki-
nesis. It is well known that Rho signaling is involved in
the progression of G1/S transition and in cytokinesis
[27, 28]. Misaligned chromosomes and aneuploidy in-
duced by PGF2a treatment of hFP-HEK cells suggests a
potential function of Rho in nuclear division as well. In
support of this, ROCK kinase, one of the downstream
effectors of Rho, has been found to exist in the same
complex with Aurora A kinase. Furthermore, depletion
of either protein by RNA interference (RNAi) induces
G2/M cell cycle arrest and abnormal mitotic spindles,
with the corresponding generation of aneuploidy and
polyploidy [29]. Given that Aurora A kinase plays an es-
sential role in centrosome maturation and bipolar spin-
dle assembly, and the evidence that both Aurora A ki-
nase and ROCK exist in the same genetic pathway, lend
additional support to the idea that ROCK and its activa-
tor, Rho, are involved in the normal functions of the cen-
trosome, spindle assembly, and equal partitioning of the
chromosomes. Cdc42 and its effector, mDia3, were re-
cently found to be involved in the bi-orientation and sta-
bilization of spindle microtubule attachment to the kine-
tochore, which thereby regulates chromosome align-
ment in metaphase [30]. A possible mechanism that
could link PGF2a activation of Rho signaling with the
role of Cdc42 in chromosome alignment involves the
protein, ECT2, which is a guanine nucleotide exchange
factor for the Rho, Rac, and Cdc42 GTPases. Thus, in-
appropriate activation of Rho in PGF2a-treated hFP-
HEK cells could interfere with the bi-attachment of the
kinetochore to microtubules by depleting ECT2 activ-
ity toward Cdc42. Evidence supporting this mechanism
is that expression of dominant negative forms of
ECT2, and RNAi knockdown of ECT2 protein, impair
microtubule attachment to kinetochores and cause
prometaphase delay and abnormal chromosomal segre-
gation [31]. 
Genomic instability involving the gain or loss of chro-
mosomes (aneuploidy) is a hallmark of cancer. One of
the important features of cancer-associated aneuploidy is
that it appears to be a very dynamic process. Studies sug-
gest that pre-existing aneuploidy in transformed cells is
usually associated with elevated rates of subsequent
chromosome instability [32]. As reviewed in the Intro-
duction, PGF2a has been found to act as a tumor pro-
moter in a mouse model of skin carcinogenesis. A possi-
ble basis for this tumor-promoting activity might, there-
fore, involve a PGF2a-mediated increase in genomic
instability caused by interference with proper function-
ing of the mitotic spindle and equal partitioning of the
chromosomes. If true, this would suggest that PGF2a
could exert a tumor-promoting action in the very early
stages of carcinogenesis. 
Support for a tumor-promoting action of prostanoids in
general comes from the well-known protective effects of
non-steroidal anti-inflammatory drugs on the develop-
ment of a number of cancers, including colon, breast, and
oral cancer [2, 3]. It is interesting that the tissue concen-
trations of both PGE2 and PGF2a are frequently highly el-
evated in inflammation and cancer [1]. Also intriguing is
that epithelial cells from high-grade inflammatory
bronchi, for example, show a degree of aneuploidy that is
similar to that observed in tumor cells. Likewise, centro-
some amplification and multipolar mitosis have been
found to occur in the early stages of inflammation and are
characteristic of tumors as well [33]. Thus, inflammatory
conditions share several tumor-specific features that are
likely to be maintained by the combined actions of PGE2,
PGF2a and possibly other prostanoids. This study has
shown that PGF2a can induce multipolar mitosis and in-
crease aneuploidy in cells transfected with the human FP
receptor. Further work will be needed to see if the actions
of PGF2a acting through FP receptors are responsible for
some of the genomic instability observed in tumors, and
whether FP receptor activation is directly involved with
early stages of tumorigenesis. 
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